短程放疗联合巩固化疗后临床完全缓解直肠癌的非手术管理
本研究纳入90例I–III期直肠腺癌患者,接受短程放疗联合巩固化疗,初始评估临床完全缓解(cCR)者43例行非手术管理(NOM),非cCR者43例行手术。中位随访30.1个月,NOM队列持续cCR率79%,2年局部无再生生存率81%,局部再生患者均成功挽救;cCR组区域控制、无远处转移生存、无病生存和总生存均优于非cCR组。
要点
- 短程放疗联合巩固化疗后cCR者行NOM可行,2年局部无再生生存率81%。
- cCR组2年无远处转移生存和无病生存均优于非cCR组。
- 持续NOM患者未观察到晚期3级及以上胃肠或泌尿生殖毒性。
核心结论
- 短程放疗联合巩固化疗后对达到cCR的直肠癌患者行非手术管理是可行的器官保留策略,但需进一步前瞻性研究验证。
研究设计与样本
- 单中心研究纳入2018年1月至2019年5月间90例I–III期直肠腺癌患者,均接受短程放疗联合巩固化疗。
- 可评估初始反应者中,cCR者43例行NOM,非cCR者43例行手术。
主要发现
- 中位随访30.1个月,NOM队列持续cCR率为79%(30/38)。
- 初始cCR组2年局部无再生生存率为81%(95%CI 70%–94%),局部再生患者均成功挽救。
关键数值与推荐
- 临床反应通过直肠指检、盆腔磁共振成像和内镜评估。
- 持续NOM患者未观察到晚期3级及以上胃肠或泌尿生殖毒性。
临床怎么用
- 对短程放疗联合巩固化疗后经直肠指检、磁共振和内镜评估达到cCR的直肠腺癌患者,可考虑NOM并密切随访。
- 局部再生患者仍可通过挽救手术成功处理。
局限性
- 研究为非随机设计,样本量有限(n=90),随访时间较短(中位30.1个月)。
- 需进一步前瞻性研究评估该策略的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to determine the clinical efficacy and safety of nonoperative management (NOM) for patients with rectal cancer with a clinical complete response (cCR) after short-course radiation therapy and consolidation chemotherapy. METHODS AND MATERIALS: Patients with stage I-III rectal adenocarcinoma underwent short-course radiation therapy followed by consolidation chemotherapy between January 2018 and May 2019 (n = 90). Clinical response was assessed by digital rectal examination, pelvic magnetic resonance imaging, and endoscopy. Of the patients with an evaluable initial response, those with a cCR (n = 43) underwent NOM, and those with a non-cCR (n = 43) underwent surgery. The clinical endpoints included local regrowth-free survival, regional control, distant metastasis-free survival, disease-free survival, and overall survival. RESULTS: Compared with patients with an initial cCR, patients with initial non-cCR had more advanced T and N stage (P = .05), larger primary tumors (P = .002), and more circumferential resection margin involvement on diagnostic magnetic resonance imaging (P < .001). With a median follow-up of 30.1 months, the persistent cCR rate was 79% (30 of 38 patients) in the NOM cohort. The 2-year local regrowth-free survival was 81% (95% confidence interval [CI], 70%-94%) in the initial cCR group, and all patients with local regrowth were successfully salvaged. Compared with those with a non-cCR, patients with a cCR had improved 2-year regional control (98% [95% CI, 93%-100%] vs 85% [95% CI, 74%-97%], P = .02), distant metastasis-free survival (100% [95% CI, 100%-100%] vs 80% [95% CI, 69%-94%], P < .01), disease-free survival (98% [95% CI, 93%-100%] vs 71% [95% CI, 59%-87%], P < .01), and overall survival (100% [95% CI, 100%-100%] vs 88% [95% CI, 79%-98%], P = .02). No late grade 3+ gastrointestinal or genitourinary toxicities were observed in the patients who underwent continued NOM. CONCLUSIONS: Short-course radiation therapy followed by consolidation chemotherapy may be a feasible organ preservation strategy in rectal cancer. Additional prospective studies are necessary to evaluate the safety and efficacy of this approach.
引用
- Chin RI, Roy A, Pedersen KS, et al. Clinical Complete Response in Patients With Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Nonoperative Management. Int J Radiat Oncol Biol Phys. 2021. PMID: 34653579. doi:10.1016/j.ijrobp.2021.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。